STOCK TITAN
  1. Home
  2. News
  3. IDXX

Idexx Laboratories, Inc. - IDXX STOCK NEWS

Welcome to our dedicated news page for Idexx Laboratories (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on Idexx Laboratories.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Idexx Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Idexx Laboratories's position in the market.

News
IDEXX Laboratories to Release 2024 First Quarter Financial Results
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the release of its 2024 first quarter results on May 1, 2024, with an analyst conference call scheduled. The Company is a global leader in pet healthcare innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
earnings
-
News
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will participate in two upcoming conferences to discuss pet healthcare innovation. Brian McKeon and Tina Hunt will speak at the BofA Securities Animal Health Virtual Summit, while Jay Mazelsky will present at the Raymond James Institutional Investors Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
-
News
IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect
Rhea-AI Summary
IDEXX Laboratories, Inc. launches Vello, a pet owner engagement solution, showing an average 19% reduction in no-show rates. Vello streamlines communication between veterinary practices and pet owners, improving practice efficiency and client relationships. Key features include automated appointment reminders, health service reminders, online scheduling, pet owner mobile experience, two-way texting, and pre-appointment instructions. Vello will be available for ezyVet, Neo, and Cornerstone software in the U.S. in March 2024 and Canada in Q2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
News
IDEXX Announces Fourth Quarter and Full Year Results
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) achieved 9% revenue growth in the fourth quarter of 2023, driven by 11% reported and 10% organic growth in CAG Diagnostics recurring revenue. The company also delivered fourth quarter EPS of $2.32, an increase of 13% as reported and 17% on a comparable basis. IDEXX provided an initial outlook for 2024 revenue of $3,930 million - $4,040 million, reflecting growth of 7.5% - 10.5% reported and 7% - 10% organic, and estimated 2024 EPS of $10.84 - $11.33, an increase of 8% - 13% as reported and on a comparable basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
-
News
IDEXX Laboratories to Release 2023 Fourth Quarter and Full Year Financial Results
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) to release 2023 fourth quarter and full year financial results on February 5, 2024. The company will conduct an analyst conference call at 8:30 a.m. ET. Individuals can access a live webcast and transcript of prepared remarks on the IDEXX website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
earnings
-
News
IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) expands its Fecal Dx antigen testing platform to include Cystoisospora, a common intestinal parasite affecting young dogs and cats. The new testing offers early and accurate detection of various parasites, with the launch planned for March in North America and globally in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
News
IDEXX Announces Revolutionary Slide-Free Cellular Analyzer, IDEXX inVue Dx™ Transforming In-Clinic Workflows
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the global launch of the IDEXX inVue Dx™ Cellular Analyzer, a revolutionary slide-free cellular analyzer for cytology and blood morphology cases in veterinary practices. The platform provides reference-laboratory quality results in 10 minutes, eliminating manual workflow and image analysis steps while generating consistent, clinically actionable results for practitioners and their patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
News
IDEXX Laboratories Schedules Two Institutional Investor Events
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will participate in two upcoming institutional investor events. Jay Mazelsky, President and CEO, will join the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York on January 4, 2024, and will host an Investor and Analyst Session at VMX in Orlando, Florida on January 15, 2024, to highlight IDEXX’s new point of care analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
News
IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne Diseases
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The test uses the trusted SNAP 4Dx Plus testing platform and will be available in Europe and Asia beginning February 2024. The launch provides veterinarians with an end-to-end solution for vector-borne disease testing, including streamlined reference laboratory follow-up testing and compatibility with the SNAP Pro® Analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
News
IDEXX Laboratories Announces Third Quarter Results
Rhea-AI Summary
IDEXX Laboratories, Inc. reports third quarter revenue growth of 9% reported and 8% organic. EPS increases by 18% as reported and 16% on a comparable basis. Adjusts 2023 revenue guidance to $3,635 million - $3,650 million. Updates 2023 EPS outlook to $9.74 - $9.90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
earnings
Stock IDXX logo
Idexx Laboratories, Inc.

Nasdaq:IDXX

IDXX Rankings

#307 Ranked by Market Cap
#1334 Ranked by Stock Gains
N/A Ranked by Dividends

IDXX Stock Data

41.34B
82.19M
0.93%
92.76%
2.11%
In-Vitro Diagnostic Substance Manufacturing
Manufacturing
Link
US
Westbrook

About IDXX

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an